01—Abstract
Summary
Summary of the 8-K filed October 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (Nasdaq: INSM) disclosed in an 8-K filed October 5, 2026 that Chief Financial Officer Sara Bonstein will step down effective October 30, 2026, after nearly seven years in the role.
The filing states that the separation is not related to any disagreement with the Company on accounting practices, financial statements, internal controls, or operations. Ms. Bonstein will remain CFO through the reporting of third-quarter 2026 results and will participate in the earnings call on Thursday, October 29, 2026. The Company has commenced a search for a successor and has engaged a leading executive search firm.
Ms. Bonstein will receive the benefits set forth in Section 6.e of her Amended and Restated Employment Agreement dated April 1, 2022. In the same press release, Insmed reaffirmed its full-year 2026 revenue guidance of $1.25 billion to $1.40 billiona for BRINSUPRI (brensocatib) and $450 million to $470 million for ARIKAYCE (amikacin liposome inhalation suspension). Chair and CEO Will Lewis stated that the Company is well positioned to reach cash flow positivity next year and cited the company's raising of more than $4.2 billion in capital during Ms. Bonstein's tenure.
Third-quarter 2026 financial results are scheduled for release on October 29, 2026, with a conference call beginning at 8:00 a.m. ET that day.
For investors, the key items are the CFO transition timing, the continuity of the Q3 reporting process with the outgoing CFO still in place, and the reaffirmed 2026 product revenue guidance. The filing does not name a successor, and the press release is furnished under Item 7.01 rather than filed.
02—Key points
Key Highlights
- CFO Sara Bonstein will step down effective October 30, 2026, after nearly seven years; the search for a successor is underway with an executive search firm engaged.
- The filing states the departure is not related to any disagreement on accounting practices, financial statements, internal controls, or operations.
- Full-year 2026 guidance reaffirmed: BRINSUPRI revenue of $1.25 billion to $1.40 billion and ARIKAYCE revenue of $450 million to $470 million.
- Management states Insmed is well positioned to reach cash flow positivity next year, with a path to sustained top-line growth and bottom-line profitability.
- Third-quarter 2026 financial results will be released October 29, 2026, with an 8:00 a.m. ET conference call that day; Ms. Bonstein will participate.
- Ms. Bonstein will receive benefits under Section 6.e of her Amended and Restated Employment Agreement dated April 1, 2022.
- Press release is furnished under Item 7.01 and is not deemed filed for Section 18 purposes.
03—Questions
Frequently Asked Questions
Why is the CFO leaving and is there an accounting or controls issue?
The filing states Ms. Bonstein is separating from the Company and that the separation is not related to any disagreement with the Company on accounting practices, financial statements, internal controls, or operations. She cites a desire to pursue a broader leadership role.
When does the CFO transition take effect and who will report Q3 results?
Ms. Bonstein's separation is effective October 30, 2026. She will remain CFO through the third-quarter 2026 reporting and will participate in the October 29, 2026 earnings call.
Has Insmed named a replacement CFO?
No. The filing states the Company has commenced a search for its next CFO and has partnered with a leading executive search firm.
Did the company change its 2026 revenue guidance?
No. Insmed reaffirmed full-year 2026 guidance of $1.25 billion to $1.40 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE.
What is the timing of the next earnings release?
Third-quarter 2026 financial results will be released on Thursday, October 29, 2026, with a conference call beginning at 8:00 a.m. ET that day. A replay will be available through November 5, 2026.
04—Continue